STOCK TITAN

T2 Biosystems, Inc - TTOO STOCK NEWS

Welcome to our dedicated page for T2 Biosystems news (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems stock.

T2 Biosystems, Inc. (Symbol: TTOO) is a pioneering company in the field of in vitro diagnostics, dedicated to improving patient health through advanced diagnostic products. The company’s core focus is on developing rapid diagnostic tools aimed at detecting sepsis-causing pathogens and antibiotic resistance genes. Sepsis, a condition that accounts for one out of two hospital deaths, is a primary target for T2 Biosystems.

Utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, the company has launched FDA-cleared products such as the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel. These products enable faster, more accurate detection of pathogens, allowing clinicians to make informed treatment decisions earlier. T2 Biosystems is also working on an array of other diagnostic solutions targeting hemostasis, bacteria, and Lyme disease. Notably, the T2Lyme Panel is slated for commercial launch in the third quarter of 2024.

Recent achievements highlight the company’s growth and stability. T2 Biosystems has recently achieved double-digit growth in sepsis product revenue and significantly reduced its total debt by approximately 80% over the past year. The company is a leader in the rapid detection of sepsis-causing pathogens, powered by its proprietary T2 Magnetic Resonance technology. These advancements not only promise to lower mortality rates but also aim to enhance patient outcomes and reduce healthcare costs.

T2 Biosystems is committed to fostering an innovative and inclusive work environment. The company actively seeks to attract and retain top talent, encouraging a culture of growth and excellence. For those interested in joining the mission to transform medical diagnostics, open positions can be found on their website.

Rhea-AI Summary
CDC releases Hospital Sepsis Program Core Elements to optimize sepsis programs in the US. T2 Biosystems praises the action and highlights the benefits of their products in rapid sepsis detection. Sepsis is the leading cause of death in US hospitals, costing $62 billion annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.97%
Tags
none
-
Rhea-AI Summary
T2 Biosystems regains compliance with NASDAQ market value requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
none
-
Rhea-AI Summary
T2 Biosystems received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders, and received second-largest sepsis driven T2Dx Instrument order. Q2 total revenue decreased by 67%, primarily due to reduction in BARDA research contribution revenues. Cash and cash equivalents totaled $16.1 million as of June 30, 2023. The Company expects full-year sepsis and related product revenue growth of 13% to 25% compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.53%
Tags
Rhea-AI Summary
T2 Biosystems, Inc. has been granted an extension by the Nasdaq Hearings Panel to evidence compliance with Nasdaq's minimum bid price and market value of listed securities requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.59%
Tags
none
-
Rhea-AI Summary
T2 Biosystems, Inc. plans to participate in two upcoming investor conferences in August 2023: Canaccord Genuity Annual Growth Conference and Sidoti Micro-Cap Conference. Interested parties can access live and recorded webcasts of the presentations on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Summary
T2 Biosystems, Inc. will report financial results for Q2 2023 on August 7, 2023. The conference call will be held at 4:30 p.m. Eastern Time. Investors can access the live webcast at www.t2biosystems.com and dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) to listen to the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.15%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
none
-
Rhea-AI Summary
T2 Biosystems receives FDA Breakthrough Device designation for Candida auris diagnostic test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
Rhea-AI Summary
T2 Biosystems announces record sepsis test panel orders and strengthened balance sheet in Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16%
Tags
Rhea-AI Summary
T2 Biosystems announces conversion of term loan into common stock and preferred stock, reducing outstanding principal amount by $10 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
none

FAQ

What is the current stock price of T2 Biosystems (TTOO)?

The current stock price of T2 Biosystems (TTOO) is $0.51 as of November 22, 2024.

What is the market cap of T2 Biosystems (TTOO)?

The market cap of T2 Biosystems (TTOO) is approximately 9.5M.

What is T2 Biosystems, Inc. known for?

T2 Biosystems is known for its rapid diagnostic products that detect sepsis-causing pathogens and antibiotic resistance genes.

What are the core products of T2 Biosystems?

The core products include the T2Dx Instrument, T2Bacteria Panel, T2Candida Panel, T2Resistance Panel, and T2Biothreat Panel.

What proprietary technology does T2 Biosystems use?

T2 Biosystems uses its proprietary T2 Magnetic Resonance platform, or T2MR®, for rapid pathogen detection.

What recent financial achievements has T2 Biosystems made?

T2 Biosystems has achieved double-digit growth in sepsis product revenue and reduced its total debt by approximately 80% over the past year.

When is the T2Lyme Panel expected to launch?

The T2Lyme Panel is anticipated to be commercially available in the third quarter of 2024.

Where can I find job opportunities at T2 Biosystems?

Job opportunities at T2 Biosystems can be found on their official website.

How does T2 Biosystems aim to impact healthcare?

T2 Biosystems aims to lower mortality rates, enhance patient outcomes, and reduce healthcare costs through its rapid diagnostic products.

Who can I contact for investor-related inquiries?

For investor-related inquiries, you can contact Philip Trip Taylor at Gilmartin Group via email at ir@T2Biosystems.com or phone at 415-937-5406.

What areas of unmet medical need is T2 Biosystems targeting?

T2 Biosystems is targeting unmet medical needs in sepsis, hemostasis, bacteria, and Lyme disease.

How does T2MR® technology benefit patient care?

T2MR® technology benefits patient care by enabling faster and more accurate detection of pathogens, leading to earlier and more targeted treatment decisions.

T2 Biosystems, Inc

Nasdaq:TTOO

TTOO Rankings

TTOO Stock Data

9.55M
8.59M
10.17%
73.51%
4.78%
Diagnostics & Research
Surgical & Medical Instruments & Apparatus
Link
United States of America
LEXINGTON